Tenecteplase-associated orolingual angioedema: A case report and literature review

CONCLUSION: Although rare, OA is a potentially life-threatening complication of tenecteplase therapy and requires prompt pharmacological intervention to optimize patient outcomes. Currently, no single agent or treatment algorithm exists that has shown significant efficacy or safety in the setting of thrombolytic-associated OA. Until data are available for C1 esterase inhibitors in this application, these inhibitors should only be considered if there is continued symptom progression after intravenous administration of corticosteroids and antihistamines.PMID:38270186 | DOI:10.1093/ajhp/zxad334
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Source Type: research